English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background: The fear of hypoglycemia is the strongest barrier when patients with type 1 diabetes mellitus consider physical activity. There is still a lack of information regarding pre- and post-exercise therapy adaptation strategies with respect to different exercise intensities corresponding to the three phases of lactate metabolism. Objectives: The aim of this experimental, cross-sectional study was to investigate exercise intensity-dependent, short-acting insulin reductions to avoid hypoglycemia, applying standardized exercises using insulin degludec (®Tresiba/Novo Nordisk, Denmark). Methods: Seven male participants with type 1 diabetes mellitus were switched to insulin degludec. Intensities for the 30 minutes continuous cycle ergometer exercise tests were set at 5% below (A) and above (B) the lactate turn point 1, and below (C) and above (D) the lactate turn point 2. Reductions in short-acting insulin were applied as following: by 25% for intensity A, by 50% for intensity B and by 75% for intensities C and D four hours before the start of exercise and immediately after exercise. Blood glucose, interstitial glucose, lactate, catecholamines, cortisol, IGF-1 and glucagon were measured. Results: No hypoglycemic events occurred, but linear blood glucose decreases were observed: 2.01 ± 1.04 mmol.L-1, P = 0.35 (A), 3.00 ± 1.54 mmol.L-1, P = 0.48 (B), 3.42 ± 2.34 mmol.L-1, P = 0.40 (C), and 3.70 ± 3.36 mmol.L-1, P = 0.12 (D). Adrenaline, noradrenaline and IGF-1 (B, C, D, not A), dopamine (C, D, not A and B) and cortisol (A, C, D, not B) increased significantly from baseline, but not glucagon (P > 0.05). Interstitial glucose showed no post-exercise hypoglycemia. Conclusions: The applied therapy adaptation before and after exercises was adequate to avoid hypoglycemia while using an ultra-long-acting insulin.

Short-Acting Insulin Reduction Strategies for Continuous Cycle Ergometer Exercises in Patients with Type 1 Diabetes Mellitus